LENZ Therapeutics (LENZ) Other Gross PP&E Adjustments (2020 - 2026)
LENZ Therapeutics (LENZ) reported Other Gross PP&E Adjustments of -$619000.0 for Q1 2026, up 42.1% year-over-year from -$435622.8 in Q1 2025, and down 176.42% on a QoQ basis from $810000.0 in Q4 2025.
LENZ Therapeutics (LENZ) has 7 years of Other Gross PP&E Adjustments data on file, last reported at -$619000.0 in Q1 2026.
- Quarterly Other Gross PP&E Adjustments rose 42.1% year-over-year to -$619000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$619000.0 (up 42.1% YoY) and the FY2025 annual result came in at $810000.0, up 230.86% from the prior year.
- Other Gross PP&E Adjustments retreated to -$619000.0 in Q1 2026 per LENZ's latest filing, from $810000.0 in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $32.8 million in Q1 2023 and bottomed at -$2.3 million in Q4 2023.
- The 5-year median for Other Gross PP&E Adjustments is -$578000.0 (2024), against an average of $3.5 million.
- The widest annual swing landed in 2023, when Other Gross PP&E Adjustments soared 5889.21%; it then plunged 153200.0% in 2024.
- Tracing LENZ's Other Gross PP&E Adjustments over 5 years: stood at $18.6 million in 2022, then tumbled by 112.15% to -$2.3 million in 2023, then soared by 72.54% to -$619000.0 in 2024, then soared by 230.86% to $810000.0 in 2025, then sank by 176.42% to -$619000.0 in 2026.
- Per Business Quant, the three latest LENZ Other Gross PP&E Adjustments figures stand at -$619000.0 (Q1 2026), $810000.0 (Q4 2025), and -$847000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 | -619,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -619,000.00 |
| Mar 31, 2026 | -619,000.00 |
| Dec 31, 2025 | 810,000.00 |
| Dec 31, 2025 | 810,000.00 |
| Sep 30, 2025 | -847,000.00 |
| Sep 30, 2025 | -847,000.00 |
| Jun 30, 2025 | -959,000.00 |
| Jun 30, 2025 | -959,000.00 |
| Mar 31, 2025 | -1.07 Mn |
| Mar 31, 2025 | -1.07 Mn |
| Dec 31, 2024 | -619,000.00 |
| Dec 31, 2024 | -619,000.00 |
| Sep 30, 2024 | -1.53 Mn |
| Sep 30, 2024 | -1.53 Mn |
| Jun 30, 2024 | -1.73 Mn |
| Jun 30, 2024 | -1.73 Mn |
| Mar 31, 2024 | -578,000.00 |
| Mar 31, 2024 | -578,000.00 |
| Dec 31, 2023 | -2.25 Mn |
| Dec 31, 2023 | -2.25 Mn |
| Sep 30, 2023 | -1,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | 5.17 Mn |
| Jun 30, 2023 | 5.17 Mn |
| Mar 31, 2023 | 32.76 Mn |
| Mar 31, 2023 | 32.76 Mn |
| Dec 31, 2022 | 18.55 Mn |
| Dec 31, 2022 | 18.55 Mn |
| Sep 30, 2022 | 8.05 Mn |
| Sep 30, 2022 | 8.05 Mn |
| Jun 30, 2022 | 3.24 Mn |
| Jun 30, 2022 | 3.24 Mn |
| Mar 31, 2022 | 547,000.00 |
| Mar 31, 2022 | 547,000.00 |
| Dec 31, 2021 | -5.00 Mn |
| Dec 31, 2021 | -5.00 Mn |
| Sep 30, 2021 | -3.07 Mn |
| Sep 30, 2021 | -3.07 Mn |
| Jun 30, 2021 | 1.47 Mn |
| Jun 30, 2021 | 1.47 Mn |
| Dec 31, 2020 | 1.53 Mn |
| Dec 31, 2020 | 1.53 Mn |